NorthStar Medical Radioisotopes awarded three patents for Mo-99 production process
NorthStar Medical Radioisotopes, a nuclear medicine company based out of Madison, Wis., announced this week it has been awarded three patents related to its processes for producing molybdenum-99 (Mo-99) without using highly enriched uranium.
The patents were for the company’s RadioGenix isotope separation system and two related components: the Mo-99 Source Vessel and the Technetium-99m (Tc-99m) Product Cartridge.
The RadioGenix system allows users to process different medical isotopes. The Mo-99 Source Vessel will be used in shipping Mo-99 to customers, and the Tc-99m product cartridge filters out the remaining Mo-99 from the Tc-99m and “provides cold sterilization of the final eluent.”
The company was also awarded a trademark approval for NuMolium, its brand of Mo-99.
Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.